This is indeed a classic case of the public interest versus the special interest. That is exactly what the issue is today on the floor. The Pryor-Brown-Chafee amendment closes a loophole that every expert in this field, from our Patent Office and the Food and Drug Administration to our U.S. Trade Representative, says should be closed. We are also seeking to have the prescription drug industry play by the very same rules as every other industry in our country. The third thing our amendment does, Mr. President, is guarantee that American consumers have access to affordable generic drugs as was intended by the GATT treaty.
William Pryor: “This is indeed a classic case of the public interest versus the special interest. That is exactly what the issue is…”
Editor's note · Context
Discussing the implications of the GATT treaty and the Pryor-Brown-Chafee amendment on drug pricing.
Share
More from William Pryor
No. First, the CPSC Reform Act bans lead in children's products beyond trace amounts. Under section 22, any children's product that contains lead ``shall be treated as a banned hazardous substance under the Federal Hazardous Substances…
I wish to speak on an issue that is extremely important to families all across the country--consumer product safety. I have spent the past year working with several of my colleagues to reform and reinvigorate the agency charged with…
This idea of allowing State attorneys general to assist Federal agencies with enforcement of Federal decisions is not new in this bill. This has been around for a long time. I have nine examples I want to mention very quickly. In the Fair…
Absolutely. Mr. DeMINT. Madam President, I appreciate the Senator's comments. I do wish to make it clear that while Congress has set many safety standards, it is very unusual for us to select and prescribe the technology that will be used…